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dentifying the “Optimal” Duration of
ual Antiplatelet Therapy After
rug-Eluting Stent Revascularization
avid E. Kandzari, MD,* Dominick J. Angiolillo, MD, PHD,† Matthew J. Price, MD,*
aul S. Teirstein, MD*
a Jolla, California; and Jacksonville, Florida
ncertainty regarding the appropriate duration of dual antiplatelet therapy (DAPT) with aspirin and a thien-
pyridine challenges every clinician involved in the care of patients considered for or treated with drug-
luting stents (DES). Despite guideline recommendations for extended (12 months) DAPT following percu-
aneous coronary revascularization with DES, few data are available to guide clinical decision-making
eyond consensus opinion. Yet considering the clinical implications of stent thrombosis (ST) and its unpre-
ictability in late occurring events, comprehensive assessment of the relationship between DAPT duration
nd ST over the long-term is a focus for DES-related clinical trials and an essential public health measure.
espite the potential for prolonged DAPT to reduce late-term cardiovascular events related to the progres-
ion of atherosclerosis, few studies have formally examined the safety and efﬁcacy of extended DAPT and
ts impact on late ST events. The purpose of this paper is to appraise the existing evidence regarding the
elationship between long-term DAPT and late cardiovascular events; address outstanding (and unstudied)
ilemmas related to DAPT in DES-treated patients; and propose considerations for both trial design and
linical practice. (J Am Coll Cardiol Intv 2009;2:1279–85) © 2009 by the American College of Cardiology
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eptember 10, 2009, accepted September 20, 2009.ear) stent thrombosis (ST) might be mitigated by
he use of dual antiplatelet therapy (DAPT) (aspi-
in plus thienopyridine) beyond that described in
arly pre-approval trials that served as a basis for
roduct labeling (1,2). Although a reanalysis of key
andomized trials comparing sirolimus- and
aclitaxel-eluting stents with bare-metal stents
BMS) through 5-year follow-up has demon-
trated a numerically higher incidence of very late
T with DES (3–5), and observational studies have
ndicated a higher risk of ST in off-label indica-
ions for both BMS and DES (6,7), few data are
vailable to guide clinical decision-making regard-
ng long-term DAPT use.
evelopment of DAPT Guideline
ecommendations: A Brief History
s a precautionary measure on the basis of trials
ssociating “early” (6 months) thienopyridine
iscontinuation with risk of DES thrombosis, an
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1280nter-society guidelines recommendation advocated 12
onths DAPT after DES placement in patients without
ontraindications and bleeding risk (8,9). In December
006, after an extensive review of existing data indicating a
umerical excess of late ST with sirolimus- and paclitaxel-
luting stents (3–5), the U.S. Food and Drug Administra-
ion advisory panel supported this empiric recommendation
f 12 months DAPT after DES placement and determined
hat these guidelines be incorporated into DES product
abeling. This recommendation was subsequently reinforced
y a multidisciplinary Science Advisory statement for in-
tructing clinical practice (2). Importantly, however, this
ecommendation was not based on any prospective random-
zed trial evidence associating extended-duration DAPT
ith a reduction in late ST; rather, the recommendation was
ased on consensus opinion derived from randomized trials
valuating thienopyridine dosing and treatment strategies
nvolving BMS in clinical scenarios outside the approved
ndications for DES (10,11) and from observational studies
ndicating lower risk of death and myocardial infarction
MI) with long-term DAPT (12,13).
Long-Term DAPT After DES
Revascularization: What Is
the Evidence Basis?
Deﬁning the potential beneﬁt of
long-term DAPT: prevention of
target- versus nontarget lesion-
related events. At present, stud-
ies examining the relationship
between DAPT and outcomes
after percutaneous coronary in-
ervention (PCI) have been limited by trial design or
ethods that have restricted their applicability to clinical
ecision-making in routine practice. Given the focus on
APT to reduce ST, discontinuation of antiplatelet therapy
hould be considered as “early,” 6 months; “late,” 6 and
12 months; and “very late,” 12 months. Whereas obser-
ational studies have consistently established early discon-
inuation of DAPT with a higher risk of ST (14–17),
dditional studies have demonstrated that long-term DAPT
ight be associated with reductions in death and MI
12,13). However, long-term DAPT, although providing
schemic benefit, might not influence stent-specific events.
n the Duke Cardiovascular Database, for example, patients
reated with DES and a 2-year DAPT duration experienced
ignificantly lower rates of death and MI compared with
ES- and BMS-treated patients treated with shorter du-
ation DAPT, although rates of ST were not reported (12).
n addition, in a recent observational study of 749 diabetic
atients who underwent percutaneous revascularization
ith either BMS or DES, a longer duration (i.e., 6
bbreviations
nd Acronyms
MS  bare-metal stent(s)
APT  dual antiplatelet
herapy
ES  drug-eluting stent(s)
I  myocardial infarction
CI  percutaneous
oronary intervention
T  stent thrombosisonths) of clopidogrel use was associated with a lower lncidence of death or MI over 2 years of follow-up, although
he treatment effect did not differ according to stent type
13). For patients who discontinued clopidogrel 6 months
n this study, the incidence of death or MI were similar,
rrespective of treatment with BMS or DES. Thus, the
enefit of long-term DAPT, especially in patients at high
isk for recurrent ischemic events (e.g., acute coronary
yndromes), might be related more to prevention of vascular
hrombotic events due to progression of atherosclerosis
ather than to the site of prior stent placement. In the only
rospective, randomized trial to date, the CHARISMA
Clopidogrel for High Atherothrombotic Risk and Ischemic
tabilization, Management and Avoidance) trial demon-
trated a significant reduction in late (median follow-up 27
onths) ischemic events with long-term aspirin and clopi-
ogrel compared with aspirin and placebo for patients with
stablished vascular disease (18). Although a reduction in
ubsequent MI and stroke with prolonged DAPT was
bserved in patients with prior MI, stroke, or symptomatic
eripheral arterial disease, no benefit was identified among
hose with established vascular disease but without a prior
vent.
nfluence of DAPT on Late ST:
ffect or Epiphenomenon?
rials examining the relationship between DAPT discontinuation
nd ST. A common statistical misinterpretation is to asso-
iate 2 potentially independent observations (e.g., thienopy-
idine discontinuation and ST) as related or causative to one
nother. It is especially common to associate a relationship
etween a common event (e.g., thienopyridine discontinu-
tion) and a rare event (e.g., late ST). This is particularly
elevant to understanding the relationship between DAPT
nd late and very late ST, given that DAPT discontinuation
s proportionate with time.
At present, observational studies specifically examining
he relationship between DAPT duration and ST events
ave more commonly demonstrated that extended DAPT
eyond 6 to 12 months is not associated with a reduction in
ate and very late ST (Table 1). In a prospective observa-
ional cohort study of 3,021 patients treated with DES and
ith follow-up through 18 months, the overall incidence of
T was 1.9% (19). Although the strongest predictor of ST
as thienopyridine discontinuation within 6 months of
tent placement, thienopyridine discontinuation after 6
onths did not predict its occurrence. Recently, a single-
enter analysis identified 30-day and 6-month discontinu-
tion but not cessation at 1 year (20) as predictors of ST. In
multicenter Korean registry of 7,221 patients undergoing
CI (43.8% DES), overall adjusted risks of death, death/
I, and target lesion revascularization were significantlyower with DES compared with BMS, even though DES
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1281ere associated with an increased risk of very late ST (21).
owever, among DES patients, continuing clopidogrel
reatment beyond 12 months was not associated with a
educed risk for late-term ST, death, or the composite end
oint of death/MI, indicating that prolonged DAPT might
ot influence late thrombotic events. Similarly, in the largest
f observational studies relating thienopyridine discontinu-
tion with ST risk, the Japan Cypher Registry investigators
eported outcomes related to thienopyridine adherence for
0,778 patients treated with sirolimus-eluting stents (22).
hrough 2-year follow-up, patients who discontinued both
spirin and thienopyridine treatment had significantly
igher rates of ST compared with those patients who
ontinued both medications. Thus, these results also under-
core the importance of aspirin treatment. However, when
iscontinuation of both antiplatelet agents was considered,
atients who discontinued thienopyridine but continued
spirin did not have an excess of ST at any time interval
valuated. Furthermore, 2-year rates of death or MI were
dentical (4.1%) in a 6-month landmark analysis comparing
atients taking and not taking thienopyridine therapy. In
Table 1. Studies Examining the Relationship Between DAPT Duration and
Authors (Ref. #)
Study
Population, n
Study
Duration Death
Airoldi et al. (19) 3,021 DES 18 months ST cases: 39% ST c
Park et al. (21) 2,873 DES patients
12-month
event-free
3 yrs HR: 1.20 (CI: 0.55–2.66)
for continuing TP
beyond 1 yr vs.
discontinuation
HR:
f
b
d
Schulz et al. (23) 6,816 DES 4 yrs 4.2% (overall) 8.6%
Roy et al. (20) 2,889 DES 1 yr N/A N/A
Kimura et al. (22) 10,778 SES 2 yrs On TP, 3.4%;
off TP, 3.4%
On
o
van Werkum
et al. (24)
21,009 DES and BMS 30.9 months N/A N/A
BMS bare-metal stent(s); CI confidence interval; DAPT dual antiplatelet therapy; DES drug-
stent(s); ST stent thrombosis; TIMI Thrombolysis In Myocardial Infarction; TP thienopyridinehe longest-term follow-up evaluating ST outcomes and phienopyridine treatment, a recent study from the ISAR
Intracoronary Stenting and Antithrombotic Regimen)
roup of 6,816 patients (4-year ST cumulative definite ST
isk 1.2%) also showed no influence of continued thienopy-
idine treatment beyond the initial 6 months for reducing
he risk of late and very late ST (23). These consistent
ndings are only countered to date by a case-controlled
bservational study from the Netherlands involving 21,009
atients for whom clopidogrel withdrawal within the initial
months was most predictive of ST events; most events
uring this time period occurred within 14 days of clopi-
ogrel cessation, underscoring the dependency on the early
nd intermediate-term antithrombotic efficacy of DAPT
24). In this particular study, however, discontinuation of
lopidogrel beyond 6 months was also significantly associ-
ted with a risk of ST, although the number of late ST
vents was low, and the strength of this relationship was
onsiderably less than at earlier time points.
alancing efﬁcacy with bleeding risk. Few studies formally
valuated compliance with intended therapy and increased
leeding risks associated with long-term DAPT, and
Very Late ST After DES Revascularization
MI ST Comments
9% Overall rate 1.9%; HR for TP
cessation: 6 months,
13.7 (CI: 4.0–46.7), 6
months, 0.94 (0.3–2.98)
Protective effect of TP on ST observed
only within ﬁrst 6 months of DES
treatment; median time to ST from
TP discontinuation: 14 days within
ﬁrst 6 months, 90 days thereafter
I: 0.07–4.11)
tinuing TP
1 yr vs.
inuation
HR: 0.54 (CI: 0.07–4.23) for
continuing TP beyond
1 yr vs. discontinuation
No reduction in major adverse events
with TP continuation beyond 1 yr
in 12-month event-free patients;
outcomes adjusting according to
propensity score model
rall) HR/day for ST at 6
months vs. 6 months:
0.98 (CI: 0.98–0.99) vs.
1.00 (CI: 0.99–1.01)
Protective effect of TP on ST observed
only within ﬁrst 6 months of DES
treatment; median time interval
from TP discontinuation to ST was
9 days within ﬁrst 6 months vs. 104
days thereafter
Odds ratios for TP
cessation: 30 days,
4.5 (CI: 2.0–10.4); 6
months, 2.4 (CI: 1.2–4.9);
1 yr, 1.7 (0.9–3.1)
Protective effect of TP on ST not
observed past 6 months; TP
compliance 73.8% in patients
presenting with ST (82.6% for early
ST, 43.8% for late ST)
%;
0.8%
No signiﬁcant difference in
deﬁnite ST at any time
interval through 730
days between on and
off TP
Adjusted event rates; discontinuation
of both aspirin and TP associated
with deﬁnite ST at any time point
HR for TP cessation: 30
days, 36.5 (CI: 8.0–167.8);
180–365 days, 5.9 (CI:
1.7–19.8)
ST also associated with stent
undersizing, TIMI ﬂow grade 3,
present malignancy, nontarget
lesion target vessel disease,
dissection, lack of aspirin,
bifurcation, and young age
stent(s); HR hazard ratio; MImyocardial infarction; N/A not available; SES sirolimus-elutingLate/
ases: 7
0.53 (C
or con
eyond
iscont
(ove
TP, 0.6
ff TP,
elutingresent guideline recommendations reflect uncertainty of
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1282ontinuing DAPT beyond 1 year (Class IIb, Level of
vidence: C) (9). In the CHARISMA trial (18), among
atients with established vascular disease, the rate of severe
leeding (fatal bleeding, intracranial hemorrhage, or bleed-
ng that resulted in hemodynamic compromise or required
lood transfusion and/or other medical intervention) was
.7%, which exceeds most estimates of ST over a similar
ime interval (3–5,23). Although this same analysis indi-
ated that bleeding events might decline beyond 9 months
f DAPT, the potential to exclude patients who discontin-
ed antiplatelet therapy for early bleeding events might
epresent an ascertainment bias and limit any definitive
onclusion that prolonged DAPT is safe should bleeding
ot occur in the first year.
an DAPT suppress all ST events regardless of cause? Fi-
ally, whether mechanisms of ST differ at variable time
ntervals after revascularization must be considered, in
ddition to the relative effect of antiplatelet therapy to
educe such risk. Within the early period after stent revas-
ularization (i.e., 30 days), the underlying mechanism of ST
ight be related to mechanical factors including residual
issection or incomplete stent apposition and expansion.
tent thrombosis occurring over later periods might be
elated to delayed healing, impaired stent endothelializa-
ion, endothelial dysfunction, abnormal vessel wall remod-
ling, and/or polymer-mediated hypersensitivity that might
ersist beyond 1 year, if not indefinitely. In such instances of
aried underlying pathology, whether DAPT might be
ufficient to suppress thrombosis is hypothetical but un-
roven. Nevertheless, cases of late DES-related thrombosis
ight also occur despite continued DAPT (25,26). Among
he 12 very late ST events in the recently reported 3-year
ollow-up of the ENDEAVOR IV (Randomized Compar-
son of Zotarolimus- and Paclitaxel-Eluting Stents in Pa-
ients With Coronary Artery Disease) trial, for example, 5
atients were taking DAPT at the time of the event, and 4
atients were receiving aspirin therapy alone (26).
lternative thienopyridine agents. At present, no compara-
ive studies examining dual antiplatelet treatment duration
ith aspirin and alternative thienopyridine agents (e.g., pra-
ugrel, ticagrelor) after DES revascularization have been per-
ormed. However, recent comparisons of clopidogrel with
rasugrel and ticagrelor among patients with acute coronary
yndromes undergoing PCI have been the first to demonstrate
ifferences in ST rates between thienopyridine agents (27,28).
mong patients taking aspirin, ST at 15 months occurred in
.4% of patients assigned to clopidogrel versus 1.1% among
hose randomized to prasugrel (p 0.001). Although most ST
vents occurred within 30 days of initial revascularization, a
enefit with prasugrel persisted beyond this timeframe through
he entire study period. Overall, however, prasugrel therapy
as associated with significantly greater bleeding risk, and
otential reductions in ischemic events must be carefully
onsidered relative to individual bleeding risk. Alternatively, 3efinite ST through 12 months was significantly less common
mong patients treated with ticagrelor compared with clopi-
ogrel (1.3% vs. 1.9%, p  0.009) without a concomitant
ncreased risk of major bleeding (28).
APT Permanent Discontinuation Versus
ransient Interruption
familiar limitation to population-based analyses related to
APT duration is that few studies have precisely deter-
ined whether thienopyridine discontinuation is perma-
ent or temporary. For instances of DAPT interruption,
ssessment of outcomes might be confounded if patients are
onsidered off thienopyridine treatment at an earlier assess-
ent but have instead later resumed therapy. Furthermore,
easons for DAPT discontinuation or transient interruption
re also poorly understood. In the PREMIER (Prospective
egistry Evaluating Myocardial Infarction: Events and
ecovery) registry of patients treated with DES for acute
I, factors associated with thienopyridine noncompliance
ithin the initial 30 days of revascularization included lower
ducation level, advanced age, avoidance of health care
ecause of cost, lack of discharge counseling, and history of
re-existing cardiovascular disease or anemia (29).
iming of ST after DAPT discontinuation. A common clinical
ncertainty related to DAPT interruption (aspirin, thien-
pyridine, or both drugs) is the relationship between time
rom DES revascularization, likelihood for ST and the
emporal relationship between discontinuation and adverse
vent. When DAPT therapy is discontinued (or inter-
upted) within the initial 6 months of DES treatment, the
ime from drug cessation to ST is brief (19,24,30); beyond
months, however, the relationship between time from
hienopyridine discontinuation and event is less distinct
19,24,30). As an example, in an overview of 161 ST cases
ooled from 84 published reports, the median time to event
as 10 days or less for patients who discontinued aspirin
nd thienopyridine therapy but 122 days for patients who
topped thienopyridine yet maintained acetylsalicylic acid
29). Only 6% of ST events occurred within 10 days in this
atter group, suggesting the relative importance of maintain-
ng aspirin treatment over thienopyridine for prevention of
arly events in circumstances requiring temporary antiplate-
et discontinuation.
afety of brief DAPT interruption and permanent discontinuation.
ecently, 2 studies have taken different approaches toward
rospectively evaluating outcomes related to intentional
hienopyridine discontinuation versus unplanned interrup-
ion. In the SENS (Non-cardiac Surgical Procedures and
rief Interruption of Dual Antiplatelet Agents within 12
onths Following Endeavor Stent Implantation) trial (n ,099), outcomes were reported among 194 patients (6.3%)
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1283ho required noncardiac surgery and DAPT discontinua-
ion within 1 year of coronary revascularization with
otarolimus-eluting stents (31). The most common reasons
or brief interruption were related to dental, orthopedic, and
ndoscopic procedures. Thirty-day perioperative adverse
vents were identified in 4 patients (2.1%; 2 deaths, 2 MI).
hree of the events occurred when surgery was performed
ithin 3 months of DES revascularization, advocating delay
f elective surgical procedures at least beyond this timeframe.
lthough the overall event rate is favorable for such high-risk
atients, whether perioperative outcomes might be further
mproved with shorter-acting, reversible P2Y12 platelet recep-
or antagonists (e.g., cangrelor, ticagrelor, or elinogrel) is
ncertain.
In comparison, the multicenter DATE (Optimal Duration
f Dual Antiplatelet Therapy After Implantation of the En-
eavor Stent) trial recently examined 1-year outcomes among
atients (n  823) treated with zotarolimus-eluting stents for
hom thienopyridine discontinuation was prespecified 3
onths after PCI (32). High-risk anatomical and clinical
omplexities (e.g., unprotected left main, recent MI) were
xcluded. At 3 months, 81% (n  666) of patients discontin-
ed thienopyridine therapy per protocol. One-year rates of
eath, MI, and ST were 0.3%, 0.2%, and 0.2%, respectively.
onversely, adverse events, including repeat revascularization,
ere more common among patients continuing DAPT, al-
hough this observation might reflect a treatment bias. Al-
hough this study is also limited in design and sample size, as
ith the SENS trial, both studies indicate that either brief
nterruption or intentional cessation of thienopyridine treat-
ent after zotarolimus-eluting stent revascularization might be
ssociated with reasonable safety and encourage additional
tudy (Table 2).
Table 2. Prospective Clinical Trials Evaluating Outcomes According to Vari
Trial Name Inclusion Group, n DAPT Duration DES Type
DAPT 20,645
12-month event-free
12 vs. 30 months* All DES (n  15
BMS (n  5,
ISAR-SAFE 6,000
6-month event-free
6 vs. 12 months* All DES
REAL-LATE 2,000
12-month event-free
12 vs. 24 months* All DES
ZEST-LATE 2,000
12-month event-free
12 vs. 24 months* SES, PES, ZES
OPTIMIZE 3,120 non-STEMI 3 vs. 12 months* ZES
SEASIDE 900 non-ACS 6 months ZES
DATE 823 non-ACS 3 months ZES
All trials currently enrolling or completed (DATE trial). *Randomized trial design.
ACS acute coronary syndrome; ARCAcademic Research Consortium; DATEOptimal Duratio
to Open Occluded Coronary Arteries; ISAR-SAFE  Intracoronary Stenting and Antithrombotic Re
paclitaxel-eluting stent(s); REAL-LATECorrelationofClopidogrel TherapyDiscontinuation inREAL-
SEASIDE Scripps Evaluation of Antiplatelet Therapies for IntermediateDurationWith the Endeavor
12 Months Following Endeavor Stent Implantation; ZES  zotarolimus-eluting stent(s); ZEST-LAPacliTaxel-Eluting Stent Implantation for Coronary Lesions–Late Coronary Arterial Thrombotic Events; othedentifying the “Optimal” DAPT Duration:
onsiderations for Clinical Trial Design
nd End Point Selection
t present, our understanding of the relationship between
ate antiplatelet therapy discontinuation and ST is based
xclusively on studies that are limited by observational
esign and unmeasured confounders. As a result, despite
uideline recommendations for extended DAPT with aspi-
in and a thienopyridine after percutaneous coronary revas-
ularization with DES (8,9), few data are available to guide
linical decision-making beyond consensus opinion. Yet
onsidering the clinical implications of ST and its unpre-
ictability in late-occurring events, comprehensive assess-
ent of ST over the long-term is a focus for DES-related
linical trial programs. As an example, the U.S. Food and
rug Administration has supported the need for well-
onducted studies to address the optimal duration of DAPT
fter DES placement with standardized end point defini-
ions that classify the occurrence of ST according to the
evel of evidence and timing of the event (33). Clinical
tudies must closely monitor patient compliance with the
ecommended DAPT duration and extended therapy; fre-
uency, duration, and implications of DAPT interruption;
eed for deferral of invasive procedures because of need for
ontinued DAPT; and the rate of bleeding complications
ssociated with DAPT. In addition, investigator-initiated
nd industry-sponsored trials are in development or enroll-
ng (Table 2) that are specifically intended to examine
hether variable durations of DAPT after DES revascular-
zation impact the outcomes of cardiovascular death, MI,
troke, and ST. Given that these studies are intended to
xamine low-frequency, late-occurring events, many will be
hallenged by the requirements for adequate sample size for
PT Regimens
Primary End Point Key Secondary End Point(s)
1. Death/MI/stroke at 33 months
2. Deﬁnite/probable ST at 33 months
GUSTO bleeding
Death/MI/stroke/TIMI major bleed at
15 months
Individual component end
points, ARC ST
2-yr cardiac death/MI ARC ST, bleeding
2-yr death/MI ARC ST, bleeding
1-yr death/MI/stroke/TIMI major bleed ARC ST
1-yr death/MI/stroke GUSTO bleeding
1-yr cardiac death/MI/ST Individual component end points
al Antiplatelet TherapyAfter Implantation of the Endeavor Stent; GUSTOGlobal Use of Strategies
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1284tatistical power and dedicated long-term follow-up. Fur-
hermore, noting the 1) variable durations of DAPT being
valuated in these trials; 2) potential differences in ST
etween thienopyridine agents (27,28) and possibly DES
34,35); 3) interindividual variability in antiplatelet therapy
esponse (36); and 4) differences in enrollment criteria
inclusion of event-free patients vs. all-comers, all DES vs.
pecific DES), it is likely that the impact of any singular trial
n clinical decision-making will be varied, and trial results
ust be weighed against their design and methods.
he dilemma for practitioners and suggestions for clinical
ractice. In light of the limitations identified with the
uidelines recommendation, current evidence raises more
uestions and leaves several outstanding issues unaddressed
n clinical practice. Especially, more detailed clinical trials
nformation is needed to refine the existing 12-month
APT recommendations, yet identifying the “optimal”
uration of DAPT for an all-comer PCI population seems
n oversimplification. Is the “optimal” duration of DAPT
he same for all DES, recognizing potential differences in
afety outcomes of cardiac death, MI, and ST? Similarly,
nderstanding the potential for inherited variation in plate-
et responsiveness and its contribution to ST (36), is there a
ole for genomic- and platelet assay-based tailored therapy
37)? What are the consequences of brief interruption of
APT for unplanned invasive procedures (e.g., noncardiac
urgery)? Is the potential benefit of long-term DAPT
utweighed by a higher risk of major bleeding? Will
easurable differences exist between clopidogrel and newer,
irect P2Y12 inhibitors (e.g., prasugrel, ticagrelor) with
rolonged therapy after PCI in real-world settings? These
utstanding issues have important implications for both
linical research and routine clinical decision-making.
The dilemma for clinicians is not simply whether it is safe
o discontinue thienopyridine treatment after DES revascu-
arization before 12 months but instead whether continuing
ong-term DAPT is both effective and safe. We believe the
ationale for a lifetime commitment to DAPT uniformly in
atients undergoing DES revascularization is unsubstanti-
ted: bleeding and economic costs of prolonged treatment
ight outweigh any potential reduction in stent thrombotic
vents, and if patients are treated with long-term (12
onths) DAPT, clinicians must recognize they are likely
reating systemic disease rather than the stent territory.
hus, long-term DAPT might have real potential benefit,
specially in patients with acute coronary syndromes or prior
hrombotic events, but the rationale should not be driven by
reduction in late or very late ST, which remains as yet
nproven. Nonetheless, until conclusive evidence is available
o revise the current recommendations for DAPT after
ES revascularization, we consider 12 months of DAPT
easonable for most patients. However, a rationale exists to
econsider DAPT prescription for individuals on the basis
f clinical presentation and risk assessment. For example,ur practice pattern is to treat patients with acute or prior
ascular events with even longer thienopyridine therapy
12 months) to prevent cardiovascular death, recurrent MI
r stroke, provided they do not have significant bleeding risk
18,27). For patients with ST, we attempt to identify the
nderlying cause on the basis of clinical, angiographic, and
ntravascular ultrasound findings; measure residual platelet
eactivity after clopidogrel; and consider treatment with
rasugrel in the absence of contraindications. Alternatively,
everal current observational studies indicate that shorter
APT duration (e.g., 12 months) might be sufficient to
educe ST risk compared with extended therapy. We believe
his may particularly apply to patients with low clinical risk
e.g., patients without acute coronary syndromes or chronic
idney disease) and simple lesion complexity, in whom the
ntirestenotic benefit of DES is important. Such clinical
ecision-making must be individualized, and the decision to
se DES in patients treated with DAPT durations shorter
han 12 months must also take into consideration the
eason(s) for abbreviated thienopyridine therapy (e.g., need
or elective but foreseeable surgery, concurrent warfarin
herapy), the relative benefit of DES over BMS, and in our
pinion, the type of DES. We welcome evidence that will
dvance our understanding of an issue that challenges every
linician involved in the care of patients considered for or
reated with DES.
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